ipamorelin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-04 and is reviewed periodically as new material appears.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | C18 column, water-acetonitrile gradient |
| Detection wavelength | 214 nm, optionally 280 nm | Amide backbone and aromatic side chains |
| Identity confirmation | Electrospray ionisation mass spectrometry | Deconvoluted mass compared with theory |
| Storage of solid | -20 °C or lower, dry and dark | Stability depends on residual moisture |
| Storage in solution | 2-8 °C, short term | Freeze-thaw cycling avoided |
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
== History == Efficacy was evaluated in AGAVE-201 (NCT04710576), a randomized, open-label, multicenter trial investigating three dosages of axatilimab in people with recurrent or refractory chronic graft-versus-host disease who had received at least two lines of systemic therapy and required additional treatment. Axatilimab was evaluated in an open-label single arm clinical trial of 79 participants with chronic graft-versus-host disease who had received at least two prior systemic treatments and required additional treatment. All participants received axatilimab 0.3 mg/kg every two weeks, until chronic graft-versus-host disease progression or unacceptable toxicity. The US Food and Drug Administration (FDA) approved axatilimab based on evidence of safety and efficacy from a clinical trial which included a total of 79 participants with chronic graft-versus-host disease after failure of two prior lines of systemic therapy. The trial was conducted at 55 sites in 13 countries, including Australia, Belgium, Canada, Germany, Greece, France, Israel, Italy, Spain, South Korea, Taiwan, the United Kingdom, and the United States. There were 24 sites in the United States. Out of 79 participants, at the approved dose of 0.3 mg/kg every two weeks, 37 participants were enrolled in the United States, and 43 participants at the trial sites outside of the United States. The FDA granted the application for axatilimab orphan drug and fast track designations for the treatment of chronic graft-versus-host disease.
BC Research Inc. is a privately owned Canadian process technology incubator, specializing in custom research, process development and technology commercialization. Headquartered in Vancouver, British Columbia, BC Research operates primarily from their Technology Commercialization and Innovation Centre on Mitchell Island in the Vancouver suburb of Richmond. This 40,000 sq-ft facility includes a 28,000 sq-ft pilot plant development area, 2,500 sq-ft laboratory space, 9,000 sq-ft of office space, as well as a small machine shop and fenced outdoor piloting space. Technologies are scaled up from concept to pilot or demonstration scale in preparation for commercialization. Engineering support is provided by sister companies NORAM Engineering and Constructors Ltd. Previously, BC Research was located at the BC Research and Innovation Complex at the south end of the University of British Columbia campus. This facility closed in November 2007. The company specialized in consulting and applied research and development in the area of plant biotechnology and environment, health and safety, process and analysis, transportation and ship dynamics.
Alternative splicing is one of the most important components that show functional complexity of genome. Modified splicing has significant effect on the phenotype that is relevance to disease or drug metabolism. A change in splicing can be caused by modifying any of the components of the splicing machinery such as splice sites or splice enhancers or silencers. Modification in the alternative splicing site can lead to a different protein form which will show a different function. Humans use an estimated 100,000 different proteins or more, so some genes must be capable of coding for a lot more than just one protein. Alternative splicing occurs more frequently than was previously thought and can be hard to control; genes may produce tens of thousands of different transcripts, necessitating a new gene model for each alternative splice.
Tellurium-128 and -130 are essentially stable. They only decay by double beta decay, with half-lives >1020 years. They constitute the major fraction of natural occurring tellurium at 32 and 34% respectively. Tellurium-132 and its daughter 132I are important in the first few days after a criticality. It was responsible for a large fraction of the dose inflicted on workers at Chernobyl in the first week. The isobar forming 132Te/132I is: Tin-132 (half-life 40 s) decaying to antimony-132 (half-life 2.8 minutes) decaying to tellurium-132 (half-life 3.2 days) decaying to iodine-132 (half-life 2.3 hours) which decays to stable xenon-132. The creation of tellurium-126 is delayed by the long half-life (230 k years) of tin-126.
Sources: en.wikipedia.org
Sack–Barabas syndrome (SBS) is an older name for vascular Ehlers–Danlos syndrome (vEDS). It is a medical condition, a subset of Ehlers–Danlos syndrome which especially affects the body's vascular system, including blood vessels and organs, and makes them prone to rupture.
The alkanes from pentane (C5H12) to octane (C8H18) are refined into gasoline, the ones from nonane (C9H20) to hexadecane (C16H34) into diesel fuel, kerosene and jet fuel. Alkanes with more than 16 carbon atoms can be refined into fuel oil and lubricating oil. At the heavier end of the range, paraffin wax is an alkane with approximately 25 carbon atoms, while asphalt has 35 and up, although these are usually cracked in modern refineries into more valuable products. The lightest fraction, the so-called petroleum gases, are subjected to diverse processing depending on cost. These gases are either flared off, sold as liquefied petroleum gas, or used to power the refinery's own burners. During the winter, butane (C4H10) is blended into the gasoline pool at high rates because its high vapour pressure assists with cold starts. The aromatic hydrocarbons are unsaturated hydrocarbons that have one or more benzene rings. They tend to burn with a sooty flame, and many have a sweet aroma. Some are carcinogenic. These different components are separated by fractional distillation at an oil refinery to produce gasoline, jet fuel, kerosene, and other hydrocarbon fractions. The components in an oil sample can be determined by gas chromatography and mass spectrometry. Due to the large number of co-eluted hydrocarbons within oil, many cannot be resolved by traditional gas chromatography. This unresolved complex mixture (UCM) of hydrocarbons is particularly apparent when analysing weathered oils and extracts from tissues of organisms exposed to oil.
=== Transcriptional variants === So far, three different transcription variants (TVs) have been described for CK1δ in humans (Homo sapiens), mice (Mus musculus), and rats (Rattus norvegicus), which are highly homologous. The alignment of all CK1δ sequences of all organisms shows a high homology in the first 399 amino acids, except for position 381. While the human transcription variants are using isoleucine, the mouse and rat sequences incorporate a valine instead. The only exception is rat TV3, which is also transcribing its nucleotide sequence into an isoleucine. After position 399, three different general structures can be observed. The first variant consists of 415 amino acids across all three organisms and is called TV1 in human and rat, while the murine counterpart is named CRAa. The shortest group of sequences consists of 409 amino acids: TV2 in humans and rats, CRAc in mice. The longest variant consists of 428 amino acids in rat (TV3) and mice (CRAb), while the human (TV3) variant is missing the second to last amino acid (threonine), resulting in a protein of a length of 427 amino acids. The various transcription variants are based on a different usage of the exons that are encoding for CSNK1D. The whole gene consists of eleven different exons and is located in humans on chromosome 17 at position 17q25.3. CSNK1D has a length of 35kb and is overlapping with the gene Slc16a3. The intersecting part is exon 11, which is located downstream of exon 10. However, it does not interfere with Slc16a3 since it is located in a non-coding area.
Spironolactone is closely related structurally to other clinically used spirolactones such as canrenone, potassium canrenoate, drospirenone, and eplerenone, as well as to the never-marketed spirolactones SC-5233 (6,7-dihydrocanrenone; 7α-desthioacetylspironolactone), SC-8109 (19-nor-6,7-dihydrocanrenone), spiroxasone, prorenone (SC-23133), mexrenone (SC-25152, ZK-32055), dicirenone (SC-26304), spirorenone (ZK-35973), and mespirenone (ZK-94679).
The Verkhovna Rada imposed sanctions against the Islamic Republic of Iran for supplying drones to Russia. The new regulations included a ban on exports of "military and dual-use goods" to the country and the "suspension of economic and financial obligations in favour" of its residents. The transit of Iranian goods and aircraft through Ukraine was also to be halted. Mykhailo Podolyak, a senior adviser to President Volodymyr Zelenskyy, stated that Ukraine intensified attacks against Russian supply lines and that preparations for the major counter-attack were being finalized in different sectors of the front. He proposed that a demilitarised zone of 100–120 kilometers (62–75 miles) from the border with Ukraine should be established inside Russia as part of a post-war settlement. Danish Prime Minister Mette Frederiksen announced that her government was to increase its military aid to Ukraine by $2.6 billion during 2023 and 2024.
Sources: en.wikipedia.org
Results are most often expressed as a percentage of total peak area from a reversed-phase separation. That figure reflects the detection wavelength, gradient and integration choices used by the laboratory. Two valid certificates can therefore quote different values for the same material without either being incorrect.
Chromatography separates components but does not identify them. Mass measurement gives an independent check that the main peak corresponds to the expected molecular mass. Used together, the two techniques detect both impurity load and structural misassignment.
Hydrolysis and oxidation are the main degradation routes in aqueous media. Loss of the C-terminal amide and oxidation of the aromatic residues are commonly reported changes. Cool storage and short working periods limit the extent of both processes.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.